Turkey: A Question of Timing: Negative Declaratory Relief in…
Istanbul’s First Instance IP Court recently dismissed a negative declaratory action (the “Case”) against our client citing the plaintiff’s…
Tagged with Regulator
APAC: Self-Medication in the Age of COVID: The Country-Specific…
Writing in the May edition of DIA’s Global Forum magazine, Toshiyoshi Tominaga of the Asia-Pacific Self-Medication Industry (APSMI) looks at the…
Aligning Combination Product Regulations in Asia-Pacific: A…
Writing in the April edition of DIA’s Global Forum magazine, Dhiraj Behl, Janine Jamieson, and Harikesh Kalonia highlight some of the regulatory…
Importance of Reliance to Support Strengthening Latin American…
Writing in the April edition of DIA’s Global Forum magazine, Maria Cristina Mota Pina of Abbvie on behalf of FIFARMA Regulatory & Biologics…
Saudi Arabia: SFDA CEO Sets Out Strategic Priorities
In a recent conversation with PharmaBoardroom, Prof. Hisham Bin Saad Al-Jadhey, CEO of the Saudi Food and Drug Authority (SFDA) outlined the…
Hisham Bin Saad Al-Jadhey – CEO, Saudi Food and Drug…
Speaking exclusively to PharmaBoardroom, Prof. Hisham Bin Saad Al-Jadhey, CEO of the Saudi Food and Drug Authority (SFDA), outlines the SFDA's key…
HSA: APAC’s Regulatory Gold Standard
As the most important pharma hub in its region, and one of the most important globally, many companies look to launch new products in Singapore first…
Choong May Ling, Mimi – CEO, Health Sciences Authority (HSA),…
Dr Choong May Ling, Mimi, CEO of Singapore’s Health Sciences Authority (HSA), one of the leading regulatory bodies in the Asia-Pacific region,…
After Brexit: Focus on the New Pharmaceutical Strategy for Europe
Writing in the February edition of DIA’s Global Forum magazine, Thomas Kühler of Sanofi R&D looks at the future of European pharma post-Brexit,…
New Drug Approvals in China in 2020
Writing in the February edition of DIA’s Global Forum magazine, Xu Wang of Novo Nordisk Pharma China and Xiaoxi Wang from the Shanghai Center for…
US FDA Drug Approvals 2020
In 2020, the US FDA's Center for Drug Evaluation & Research (CDER) approved 53 novel drugs, up from 48 in 2019, across a range of therapeutic…
What to Expect if Janet Woodcock Becomes Permanent FDA Head
Hours after President Biden was inaugurated on Tuesday 19th January 2021, Dr Janet Woodcock was named as acting commissioner for the Food and Drugs…
